

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

HCT 8

RRID:CVCL_2478

Type: Cell Line

Proper Citation

RRID:CVCL_2478

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2478

Proper Citation: RRID:CVCL_2478

Description: Cell line HCT 8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:77569](#), [PMID:8422623](#), [PMID:9809040](#), [PMID:10674020](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:31068700](#), [PMID:33389257](#)

Comments: Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCT 8

Synonyms: HCT-8, HCT8

Cross References: BTO:BTO_0002255, CLO:CLO_0003667, EFO:EFO_0002189, CLDB:cl1577, CLDB:cl1578, CLDB:cl4949, CLDB:cl5197, AddexBio:C0009017/4907, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, BCRC:60303, BioSample:SAMN03473138, cancercellines:CVCL_2478, CCRID:1101HUM-PUMC000104, CCRID:3101HUMTCHu18, CCRID:4201HUM-CCTCC00201,

CCTCC:GDC0201, Cell_Model_Passport:SIDM00786, ChEMBL-Cells:CHEMBL3308035, ChEMBL-Targets:CHEMBL613510, CLS:300210, ColonAtlas:HCT8, Cosmic:887226, Cosmic:948853, Cosmic:983738, Cosmic:988873, Cosmic:1043814, Cosmic:1310946, Cosmic:1479593, Cosmic:1609484, Cosmic:1676735, Cosmic:2267316, Cosmic:2301980, Cosmic:2651867, DepMap:ACH-001084, ECACC:90032006, EGA:EGAS000001000610, GEO:GSM206504, GEO:GSM274709, GEO:GSM274710, GEO:GSM274723, GEO:GSM513910, GEO:GSM514294, GEO:GSM827344, GEO:GSM1346876, GEO:GSM1374523, GEO:GSM1374524, GEO:GSM1448162, ICLC:HTL99005, IGRhCellID:HCT8, IZSLER:BS TCL 97, KCB:KCB 2011103YJ, KCLB:10244, LINCS_LDP:LCL-1198, MetaboLights:MTBLS227, PharmacDB:HCT8_519_2019, Progenetix:CVCL_2478, PubChem_Cell_line:CVCL_2478, Wikidata:Q54882008

ID: CVCL_2478

Hierarchy: cvcl_3449

Record Creation Time: 20220427T220321+0000

Record Last Update: 20260920T003525+0000

Ratings and Alerts

No rating or validation information has been found for HCT 8.

No alerts have been found for HCT 8.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 978 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lentz RW, et al. (2026) Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. *Frontiers in oncology*, 16, 1721685.

Liang X, et al. (2026) Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. *Cell death discovery*, 12(1), 92.

Duan X, et al. (2026) DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. *Cancer immunology research*, 14(6), 900.

Liang J, et al. (2026) DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer. *Cell reports*, 45(8), 117719.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Cheng H, et al. (2026) Cholesterol Reprograms Oxysterol Metabolism via the LOX1/CH25H/CYP7B1 Signaling Axis to Drive Multidrug Resistance in Colorectal Cancer. *Human mutation*, 2026, 3675889.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Yan C, et al. (2025) Mitophagy is responsible to ionizing radiation but plays a very limited role in the radiosensitivity of adenocarcinoma cells. *Human cell*, 39(1), 12.

Pan G, et al. (2025) Colorectal cancer cell-derived exosomes induce metabolic reprogramming of cancer-associated fibroblasts to promote colorectal cancer growth. *Discover oncology*, 16(1), 2146.

Zhou R, et al. (2025) Lipid Nanoparticle-Encapsulated mRNAs Encoding Tumor-Specific Toxin Proteins Selectively Target Cancer Cells and Stimulate T-cell Infiltration. *Cancer research*, 85(19), 3706.

Bacchetti R, et al. (2025) Cryptosporidium oocyst wall proteins are true components of the oocyst wall and COWP8 is not required for parasite transmission. *PLoS pathogens*, 21(10), e1013561.

Lai X, et al. (2025) Phase separation of circCHD6-encoded 216aa protein promotes colorectal cancer metastasis. *International journal of biological macromolecules*, 331(Pt 2), 148422.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Fan W, et al. (2025) Ribosomal RNA transcription regulates splicing through ribosomal protein RPL22. *Cell chemical biology*, 32(7), 908.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Liu G, et al. (2024) Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer. *Oncology research*, 32(3), 585.

Hanna JC, et al. (2023) Mode of action studies confirm on-target engagement of lysyl-tRNA synthetase inhibitor and lead to new selection marker for Cryptosporidium. *Frontiers in cellular and infection microbiology*, 13, 1236814.

Zeng K, et al. (2023) Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 10(25), e2301088.

Khan SM, et al. (2023) Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against *Cryptosporidium parvum*. *Antimicrobial agents and chemotherapy*, 67(10), e0056923.